Michael Kaabak

Prof. Dr. Michael Kaabak

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2018 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
MKMichael Kaabak
Michael Kaabak
NBNadeen Babenko
Nadeen Babenko
RSRon Shapiro
Ron Shapiro
AZAllan Zokoyev
Allan Zokoyev
ODOlga Dymova
Olga Dymova
EKEdward Kim
Edward Kim

26 February 2013 in Pediatric Transplantation
Verified
Journal Article
Open access
PDF file
MKMichael Kaabak
Michael Kaabak
NBNadezda N. Babenko
Nadezda N. Babenko
DSDmitry V. Samsonov
Dmitry V. Samsonov
VSValery A. Sandrikov
Valery A. Sandrikov
AMAlexey A. Maschan
Alexey A. Maschan
AZAlan K. Zokoev
Alan K. Zokoev
Recipient parenchymal lymphatic cells are crucial for direct and indirect pathways of allorecognition. We proposed that alemtuzumab, being infused several weeks pretransplant could eradicate peripheral lymphatic cells and promote donor‐specific tolerance. We present here a single center, retrospective review of 101 consecutive living‐donor kidney transplantations to pediatric patients aged from seven month to 18 yr, performed between September 2006 and April 2010. Immunosupression protocol included two 30 mg doses of alemtuzumab: first given 12–29 d prior to transplantation and second at the time of transplantation. Maintenance immunosupression was based on combination of low dose and wide range CNI and mycophenolate. Patients were followed for 3.8 ± 1.4 yr and protocol biopsies were taken one month, one, and three yr post transplant. The Kaplan–Meier graft and patient survival was 96% and 97% for one yr, 89% and 93% for three yr. Biopsy proven acute rejection developed in 26% patients at one yr and in 35% at two yr, no rejections occurred beyond two yr. We conclude that alemtuzumab pretreatment prior to living related donor kidney transplantation allows to reach satisfactory middle‐term results in pediatric patients with wide range and low CNI concentrations.

3 February 2012 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
KMKuvat Momynaliev
Kuvat Momynaliev
EGE. V. Gorbatenko
E. V. Gorbatenko
ASAlexandr Shevtsov
Alexandr Shevtsov
OGO. G. Gribanov
O. G. Gribanov
NBN. N. Babenko
N. N. Babenko
MKMichael Kaabak
Michael Kaabak

10 June 2017 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
MKMichael Kaabak
Michael Kaabak
NBNadeen N. Babenko
Nadeen N. Babenko
RSRon Shapiro
Ron Shapiro
AMAlexey A. Maschan
Alexey A. Maschan
AZAllan K. Zokoev
Allan K. Zokoev
ODOlga V. Dymova
Olga V. Dymova

1 January 2016 in Transplantation Direct
Verified
Journal Article
Open access
MKMichael Kaabak
Michael Kaabak
NBNadeen N. Babenko
Nadeen N. Babenko
AZAllan K. Zokoev
Allan K. Zokoev
VKValery V. Khovrin
Valery V. Khovrin
TGTatyana N. Galyan
Tatyana N. Galyan

15 April 2013 in Transplantation
Verified
Journal Article
Closed access
MKMichael Kaabak
Michael Kaabak
NBNadezda Babenko
Nadezda Babenko
AZAlan Zokoev
Alan Zokoev
MMMargaret Morozova
Margaret Morozova
EPElena Platova
Elena Platova
SKSergey Kozlov
Sergey Kozlov